ORIGINAL RESEARCH—ED PHARMACOTHERAPYORIGINAL RESEARCH—ED PHARMACOTHERAPY: Efficacy and Safety of Flexible‐Dose Vardenafil in Men with Type 1 Diabetes and Erectile Dysfunction

Introduction Erectile dysfunction (ED) affects up to 70% of men with diabetes, occurring with a higher prevalence in those with type 1 diabetes than with type 2 diabetes. Studies investigating treatment of ED in men with diabetes have largely been conducted in a total male population with diabetes. Limited data are available on the efficacy and safety of the potent oral phosphodiesterase‐5 inhibitor vardenafil in men with ED and type 1 diabetes.